XML 198 R144.htm IDEA: XBRL DOCUMENT v3.20.4
Segment Information - Geographic Information (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue, Major Customer [Line Items]                      
Revenues $ 2,852.6 $ 3,376.1 $ 3,681.6 $ 3,534.3 $ 3,671.3 $ 3,600.1 $ 3,616.7 $ 3,489.8 $ 13,444.6 $ 14,377.9 $ 13,452.9
Long-lived assets 3,844.8       3,674.3       3,844.8 3,674.3 3,601.2
U.S.                      
Revenue, Major Customer [Line Items]                      
Long-lived assets 1,496.3       1,493.2       1,496.3 1,493.2 1,152.7
Europe                      
Revenue, Major Customer [Line Items]                      
Long-lived assets 2,321.4       2,162.9       2,321.4 2,162.9 2,442.8
Asia                      
Revenue, Major Customer [Line Items]                      
Long-lived assets 16.2       6.2       16.2 6.2 3.9
Other                      
Revenue, Major Customer [Line Items]                      
Long-lived assets 10.9       12.0       10.9 12.0 1.8
Product, net                      
Revenue, Major Customer [Line Items]                      
Revenues 2,301.6 2,690.3 2,795.7 2,904.6 2,924.8 2,894.7 2,880.3 2,680.0 10,692.2 11,379.8 10,886.8
Product, net | U.S.                      
Revenue, Major Customer [Line Items]                      
Revenues                 5,900.1 6,713.8 6,800.5
Product, net | Europe                      
Revenue, Major Customer [Line Items]                      
Revenues                 3,656.4 3,794.5 3,370.3
Product, net | Asia                      
Revenue, Major Customer [Line Items]                      
Revenues                 596.7 320.3 281.2
Product, net | Other                      
Revenue, Major Customer [Line Items]                      
Revenues                 539.0 551.2 434.8
Revenues from anti-CD20 therapeutic programs                      
Revenue, Major Customer [Line Items]                      
Revenues 419.0 560.1 478.3 520.4 600.8 595.8 576.4 517.4 1,977.8 2,290.4 1,980.2
Revenues from anti-CD20 therapeutic programs | U.S.                      
Revenue, Major Customer [Line Items]                      
Revenues                 1,897.4 2,211.9 1,903.4
Revenues from anti-CD20 therapeutic programs | Europe                      
Revenue, Major Customer [Line Items]                      
Revenues                 0.1 0.2 0.2
Revenues from anti-CD20 therapeutic programs | Asia                      
Revenue, Major Customer [Line Items]                      
Revenues                 0.0 0.0 0.0
Revenues from anti-CD20 therapeutic programs | Other                      
Revenue, Major Customer [Line Items]                      
Revenues                 80.3 78.3 76.6
Other                      
Revenue, Major Customer [Line Items]                      
Revenues $ 132.0 $ 125.7 $ 407.6 $ 109.3 $ 145.7 $ 109.6 $ 160.0 $ 292.4 774.6 707.7 585.9
Other | U.S.                      
Revenue, Major Customer [Line Items]                      
Revenues                 733.6 585.8 457.0
Other | Europe                      
Revenue, Major Customer [Line Items]                      
Revenues                 8.1 9.7 32.7
Other | Asia                      
Revenue, Major Customer [Line Items]                      
Revenues                 32.9 112.2 96.2
Other | Other                      
Revenue, Major Customer [Line Items]                      
Revenues                 $ 0.0 $ 0.0 $ 0.0